Cytokinetics (NASDAQ:CYTK – Get Free Report) had its price objective decreased by investment analysts at JMP Securities from $106.00 to $78.00 in a note issued to investors on Tuesday, Benzinga…
Read More: https://zolmax.com/investing/jmp-securities-trims-cytokinetics-nasdaqcytk-target-price-to-78-00/10498532.html
Stay updated with the latests analysis and insights fromm etfsector.com